Bristol's Maxipime antibiotic will launch in second quarter; recommended dose ranges from .5 g to 2 g b.i.d.
Executive Summary
BRISTOL-MYERS SQUIBB MAXIPIME TO BE INTRODUCED IN SECOND QUARTER, the company indicated Jan. 24. The intravenous cephalosporin antibiotic cefepime (NDA 50-679) was approved Jan. 18 for uncomplicated and complicated urinary tract infections, uncomplicated skin and skin structure infections and pneumonia ("The Pink Sheet" Jan. 22, T&G-1).